Spectrum Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

17.07.13	Spectrum Pharma To Buy Talon Therapeutics - Quick Facts (RTTNews)
08.05.12	Spectrum Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference (Businesswire)
01.05.12	Spectrum Pharmaceuticals to Present at the Deutsche Bank 37th Annual Health Care Conference (Businesswire)
26.04.12	Spectrum Pharmaceuticals Reports Record Revenues and Profits for First Quarter of 2012 (Businesswire)
23.04.12	Spectrum Pharmaceuticals Expands Manufacturing Capacity and Builds Inventory Reserves for FUSILEV® (Businesswire)
19.04.12	Spectrum Pharmaceuticals to Be Added to the S&P SmallCap 600 Index (Businesswire)
17.04.12	Spectrum Pharmaceuticals Announces First Quarter 2012 Financial Results Teleconference and Webcast (Businesswire)
16.04.12	Spectrum Pharmaceuticals Commences Tender Offer for All Outstanding Shares of Allos Therapeutics (Businesswire)
05.04.12	Spectrum Pharmaceuticals to Acquire Allos Therapeutics: Acquisition Expected to Be Accretive on a Cash Basis in Q4 of 2012 (Businesswire)
05.04.12	Spectrum Pharmaceuticals Announces Results of Apaziquone Phase 3 Clinical Trials (Businesswire)
27.03.12	Spectrum Announces Launch of New Patient-to-Patient Educational Campaign for ZEVALIN® on ZEVALIN.com (Businesswire)
12.03.12	Spectrum Pharmaceuticals to Present at the 24th Annual ROTH Conference (Businesswire)
01.03.12	Spectrum Pharmaceuticals Reports Record Revenues, Profits, and Cash Generated from Operations for the Twelve-Month Period Ended December 31, 2011 (Businesswire)
24.02.12	Spectrum Pharmaceuticals to Present at the Citi 2012 Global Health Care and the RBC Capital Markets Health Care Conferences (Businesswire)
23.02.12	Spectrum Pharmaceuticals Announces Date and Time for Its Fourth Quarter and Fiscal Year 2011 Financial Results Conference Call (Businesswire)
07.02.12	Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference (Businesswire)
31.01.12	Spectrum Pharmaceuticals In-Licenses a Novel, Long-Acting GCSF Drug in U.S. Clinical Trials from Hanmi Pharmaceuticals (Businesswire)
27.01.12	Spectrum Pharmaceuticals Strengthens Commercial Operations (Businesswire)
25.01.12	Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN® (Businesswire)
23.01.12	ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive Lymphoma; Randomized Study Published in "CANCER”, the Journal of the American Cancer Society (Businesswire)
04.01.12	Spectrum Pharmaceuticals to Present at the J. P. Morgan Healthcare Conference (Businesswire)
12.12.11	Impressive ZEVALIN® Data Highlighted at 53rd Annual Meeting of the American Society of Hematology; Spectrum to Increase Clinical Efforts to Expand ZEVALIN Indications (Businesswire)
12.12.11	Multifaceted Repositioning Campaign for ZEVALIN® Unveiled at ASH 2011, Following Recent FDA Approval to Remove Bioscan Requirement (Businesswire)
09.12.11	Spectrum Pharmaceuticals Affirms Strong Patent Protection for FUSILEV® (levoleucovorin) Through December 31, 2019 (Businesswire)
09.12.11	Ecolab China Again Named Outstanding Enterprise for Corporate Social Responsibility by China Business News (Businesswire)
09.12.11	Spectrum Pharmaceuticals Announces 19 ZEVALIN Presentations at the 53rd Annual Meeting of the American Society of Hematology (ASH) in San Diego, California, December 10-13, 2011 (Businesswire)
07.12.11	Spectrum Pharmaceuticals to Present at the Oppenheimer & Co. 22nd Annual Healthcare Conference (Businesswire)
05.12.11	Dollar General Corporation Reports Record Third Quarter Sales and Earnings; Announces $500 Million Share Repurchase Authorization (Businesswire)
05.12.11	Spectrum Pharmaceuticals Files IND Application with U.S. FDA for SPI-014 (Businesswire)
28.11.11	Spectrum Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell on Tuesday, November 29, 2011 (Businesswire)
21.11.11	FDA Approves the Removal of the Bioscan Requirement for ZEVALIN® Treatment (Businesswire)
09.11.11	Spectrum Pharmaceuticals to Present at the Lazard Capital Markets 8th Annual Healthcare Conference (Businesswire)
01.09.11	Local.com Named Preferred Supplier to PAGE Cooperative (Businesswire)
23.02.11	Phase 3 Study of VX-770 Showed Profound and Sustained Improvements in Lung Function (FEV1) and Other Measures of Disease Among People With a Specific Type of Cystic Fibrosis (Businesswire)
29.11.10	FDA Accepts for Review Spectrum’s Response on FUSILEV® as a Class 2 Submission, and Establishes April 29, 2011 as PDUFA Action Date (Businesswire)
03.11.10	Spectrum Pharmaceuticals Receives Nearly $1 Million in Grants for Qualifying Therapeutic Discovery Projects (Businesswire)
12.01.10	Spectrum Pharmaceuticals Completes Enrollment in Second of Two Phase 3 Pivotal Trials for Apaziquone in Non-Muscle Invasive Bladder Cancer (Businesswire)
12.11.09	Spectrum Pharmaceuticals Announces Third Quarter 2009 Corporate Update; ZEVALIN® Sales up 80% over Third Quarter 2008 (Businesswire)
20.10.09	Spectrum Pharmaceuticals, Inc. Ranked #22 Fastest Growing Company in North America on Deloitte’s 2009 Technology Fast 500™ (Businesswire)
13.08.09	Spectrum Pharmaceuticals Announces Second Quarter 2009 Corporate Update (Businesswire)
06.08.09	Spectrum Pharmaceuticals Acquires Full Rights and Intellectual Property for RenaZorb® for All Fields of Use (Businesswire)
18.05.09	Spectrum Pharmaceuticals Announces First Quarter 2009 Corporate Update and Pipeline Review (Businesswire)
16.03.09	Spectrum Pharmaceuticals Acquires 100% of ZEVALIN®, an FDA-Approved, Proprietary, Biological Drug for Non-Hodgkin’s Lymphoma (Businesswire)
23.02.09	Spectrum Pharmaceuticals Poised to Acquire 100% Interest in RIT Oncology LLC™ Joint Venture upon CTI's Fulfillment of Closing Conditions (Businesswire)
07.11.08	Spectrum Pharmaceuticals Announces Third Quarter Corporate Update and Pipeline Review (Businesswire)
28.10.08	Spectrum Pharmaceuticals to Present at Seventh Annual BIO Investor Forum (Businesswire)
22.04.08	Spectrum Pharmaceuticals Provides an Update on Ozarelix in BPH (Businesswire)
21.04.08	Spectrum Pharmaceuticals to Provide an Update on Ozarelix in BPH on Tuesday, April 22, 2008 (Businesswire)
24.03.08	Spectrum Pharmaceuticals Presents Data on SPI-1620, a Novel Adjunct to Cancer Therapy, at the 6th International Symposium on Targeted Anticancer Therapies (Businesswire)
26.11.07	Spectrum Pharmaceuticals to Present at the Piper Jaffray 19th Annual Healthcare Conference (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	71.38	1.88 %	K V
UBS Group	28.06	1.41 %	K V
Part Grp Hldg	1’267.00	1.04 %	K V
Swiss Re	129.90	0.93 %	K V
ABB	49.42	0.82 %	K V
Geberit	524.00	0.04 %	K V
Alcon	78.02	0.03 %	K V
Givaudan	3’869.00	-0.28 %	K V
CieFinRichemont	121.05	-0.70 %	K V
Sonova Hldg	301.40	-0.86 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Spectrum Pharmaceuticals IncShs

Aktien Top/Flop

Meistgelesene Nachrichten